UCP2 and hepatocellular carcinoma: Moreover, it was published that UCP-2 silencing in human hepatocellular carcinoma (HepG2) cells decreases lactate production and increases the ATP:ADP ratio, indicating that UCP-2 favors glycolytic pathways [21].